CliffBio
small molecule

BRYNOVIN

SITAGLIPTIN HYDROCHLORIDE

Loss of exclusivityOctober 2040latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameBRYNOVIN
Active ingredientSITAGLIPTIN HYDROCHLORIDE
StrengthEQ 25MG BASE/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2025
Marketing statusRX

Listed patents

PatentExpiresType
12295953October 2040product
11944621October 2040product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

BRYNOVIN patent cliff — loss of exclusivity October 2040 | CliffBio